ONYX-015 is an E1B-deleted adenovirus that replicates in and causes lysis of p53-deficient cancer cells selectively. To study the efficiency of intratumoral (i.t.) spread by ONYX-015, we infected specific fractions of tumor cells (two p53-deficient tumor lines and one p53 functional line) in vitro before subcutaneous inoculation into nude mice. Infection of as few as 5% of p53 Ϫ tumor cells prevented tumor development in all cases; infection of 1% of p53 Ϫ tumor cells resulted in significant growth inhibition but did not prevent tumor formation. In contrast, infection with ONYX-015 had no significant effect on p53 ϩ tumor formation. These data suggested that replication-dependent tumor cell lysis and spread was occurring, but that tumor destruction might be improved by increasing i.t. virus distribution. Two treatment parameters were then varied to determine whether virus distribution, and consequently efficacy, could be improved. Divided i.t. injections of virus were more efficacious than a single injection of the same total dose. Likewise, increasing the volume of the viral suspension for i.t. injection allowed better distribution within the tumor mass and increased efficacy. These results have implications for the treatment of cancer patients with viral agents.
N ovel anti-cancer treatments with improved efficacy and decreased toxicity are needed. Therapies targeted to biological or genetic alterations specific to cancer cells may have a greater therapeutic index between cancer cells and normal cells, thus resulting in improved efficacy compared with existing treatments. For example, cancer gene therapy approaches are designed to specifically target cancer cells through gene replacement, oncogene inactivation, drug-inactivating enzyme expression, or immunomodulation,. [1] [2] [3] Replication-incompetent viruses (e.g., adenoviruses (Ads), retroviruses, adeno-associated viruses, and herpes viruses) are being used as shuttle vectors to deliver genes of interest to tumor cells. 4, 5 In a similar yet distinctly different approach, selectively replicating viruses are being developed to specifically eradicate tumor cells by replication-dependent mechanisms (including cell lysis) after infection. 6 -8 One of the main difficulties encountered in solid tumor therapy with replication-incompetent viruses, as well as other macromolecular agents (e.g., monoclonal antibodies (Abs)), has been the inability to efficiently infect or bind cancer cells within a tumor mass. 9, 10 Physical barriers to the dispersion of such agents within a solid tumor include intratumoral (i.t.) pressure gradients, limited extravasation from blood vessels, and extracellular matrix molecules. 9 The infection efficiency of tumor cells appears to be low in early phase clinical trials with viral gene therapy vectors after direct i.t. injection. 1 Although these factors may limit the effectiveness of nonreplicating virus therapies, it is unknown how these limitations will affect the antitumoral efficacy of replication-competent viruses. Replication and spread of a virus within a solid tumor could theoretically overcome the problem of inefficient cancer cell infection seen with nonreplicating viruses.
We carried out studies to assess the efficiency of i.t. spread by ONYX-015, a selectively replication-competent Ad. We subsequently studied the relationship between i.t. distribution of ONYX-015 and antitumoral efficacy. Experiments using preinfection of tumor cells before inoculation into mice demonstrated that i.t. virus distribution is a critical determinant of antitumoral efficacy. Subsequently, using established tumor xenografts, i.t. injection parameters were varied to optimize virus distribution. Improving the distribution of ONYX-015 within the tumors resulted in significantly improved efficacy.
MATERIALS AND METHODS

Cell lines and virus
ONYX-015 (dl1520) is a chimeric human group C Ad (Ad2 and Ad5) that does not express the 55-kDa product of the E1B gene. 11 As a result, ONYX-015 is inhibited for replication in cells with functional p53 and yet replicates in tumor cells lacking functional p53. 6 All Ads were grown on the human embryonic kidney cell line HEK293 as described previously. 6 The titer of purified virus was determined by a plaque assay on HEK293 cells. The negative control virus was prepared by ultraviolet (UV)-irradiating the virus sample with three consecutive cycles of 120,000 J in a UV Stratalinker.
HLaC human squamous cell carcinoma cells of the larynx were obtained from Dr. Dan Von Hoff (Cancer Therapy and Research Center, San Antonio, Tex). The C33A cervical and U87 glioblastoma tumor cell lines were obtained from the American Type Culture Collection (Manassas, Va). As described previously, C33A cells have mutant p53, U87 cells have a normal p53 gene sequence and function, and HLaC cells have a normal p53 gene sequence but lack the p53-mediated G 1 -S phase cell cycle arrest in response to ␥-irradiation.
12 Cells were grown in Dulbecco's modified Eagle's medium with high glucose and supplemented with 10% fetal bovine serum, 4 mM L-glutamine, 0.1 mM nonessential amino acids, and penicillin (100 U/mL) and streptomycin (100 g/mL).
Animals and animal care
Female athymic nu/nu mice were obtained from HarlanSprague-Dawley (Indianapolis, Ind) at 4 -6 weeks of age and quarantined for 2 weeks before entry onto studies. During and after the quarantine period, mice were housed four per cage in Allentown M1 cages fitted with microisolator tops and allowed access to Purina rodent chow 5001 and tap water ad libitum. Federal guidelines for animal care were strictly followed.
Preinfection and mixing experiments
C33A and HLaC cells are sensitive to ONYX-015 replication and lysis, whereas U87 cells are highly resistant (normal p53 gene sequence). C33A, HLaC, and U87 tumor cells were infected with ONYX-015 at a multiplicity of infection of 10 for 3 hours, washed with phosphate-buffered saline (PBS) three times, and pelleted by low-speed centrifugation. Infected cells were then immediately resuspended in Dulbecco's modified Eagle's medium and mixed with an uninfected cell suspension at various ratios, resulting in suspensions with 20% or 5% of cells infected (n ϭ 4 inocula per group for C33A; n ϭ 5 per group each for HLaC and U87); the C33A study also included a 1% preinfection group (n ϭ 4 inocula). U87 cells were also infected with wild-type Ad5 and mixed with uninfected cells to give ratios of 20% and 5%. Tumor cells prepared for inoculation into control animals were handled in identical fashion but without preinfection (n ϭ 8 inocula for C33A; n ϭ 5 each for HLaC and U87). A total of 10 7 cells were then injected in 200-L amounts into the flanks of nude mice. Afterward, injection sites were monitored biweekly for tumor growth.
Studies of repeated versus single i.t. injection regimens
HLaC cells (5 ϫ 10 6 ) were injected subcutaneously (s.c.) into the flanks of female nu/nu mice. Once tumors reached a volume of ϳ75 mm 3 , the mice were randomly allocated into three treatment groups (n ϭ 8 per group). The single treatment group received a single i.t. injection of 5.0 ϫ 10 8 plaque-forming units (PFU) of ONYX-015 divided into four quadrants, whereas the multiple dose group received identical injections of 10 8 PFU daily for 5 consecutive days ( Table 1 ). The single dose group received injections of vehicle in identical fashion to the multiple dose group on days 2-5. Control tumors received UV-inactivated virus in identical fashion to the multiple dose group (daily for 5 days). Tumor volumes were determined biweekly; animals were sacrificed when their tumor reached 1000 mm 3 .
Effects of virus suspension volume on efficacy and i.t. distribution C33A cells were injected into the flanks of 7-to 10-week-old female nu/nu mice, and animals were randomly allocated into two treatment groups when the resulting tumors reached 225 mm 3 . Each group received i.t. injections of 3 ϫ 10 9 PFU of virus suspended in a total volume of either 100 L (high volume; n ϭ 8) or 40 L (low volume; n ϭ 8) of PBS. One-fourth of the total virus suspension volume was administered into each of four tumor quadrants (a single, multisite treatment). Negative control mice received a total dose equivalent to 3 ϫ 10 9 PFU of UV-inactivated virus given in identical fashion to the high volume (100 L) group (n ϭ 8). To control for nonspecific injection volume effects, tumors were injected with a PBS injection volume of either 100 L (low treatment volume group) or 40 L (high treatment volume group) on day 3, and with 100 L on day 5 (all three groups). Tumor measurements were taken biweekly.
To assess virus distribution within tumors after injection with low (40 L) or high (100 L) suspension volumes, nude mice with s.c. C33A tumors (ϳ200 mm 3 ) were treated with a single i.t. dose of 1 ϫ 10 8 PFU of ONYX-015 and euthanized 3 or 5 days postinjection. On excision, tumors were fixed in formalin and embedded in paraffin. In situ hybridization for Ad DNA was used to detect cells infected with ONYX-015. Slides were deparaffinized in xylene, hydrated through ethanols, digested with proteinase K and postfixed in 4% paraformalde- ‫ء‬Number of tumors formed/number of tumor cell inoculation sites. p53-deficient (C33A and HLaC) and normal p53 (U87) tumor cells were infected with ONYX-015 or Ad5 (wild-type adenovirus, positive control) in vitro and subsequently mixed with an uninfected cell suspension, resulting in preinfection of 20%, 5%, or 1% of cells. A total of 10 7 cells were then injected s.c. into the flanks of nude mice. Inoculation sites were examined biweekly for 8 weeks for tumor formation. hyde. Hybridization was carried out overnight at 37°C with 0.5 g/mL biotinylated Ad DNA probe (Enzo Diagnostics, Farmingdale, NY). After three successive washes in 1ϫ standard saline citrate at 55°C, an alkaline phosphatase-conjugated anti-biotin Ab (Vector Laboratories, Burlingame, Calif) was applied. Nitro blue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate was used as the chromagen, and slides were counterstained with nuclear fast red.
Statistical methods
The unpaired Student's t test was used to compare the final tumor volumes between different treatment groups (␣ ϭ 0.05). Tumor regressions were described using standard terminology including complete response (total tumor regression), partial response (Ն50% decrease in tumor volume), and minor response (Ͻ50% decrease in volume).
RESULTS
Preinfection and mixing studies
Tumors developed and grew at all sites inoculated with uninfected C33A, HLaC, or U87 tumor cells within 2 weeks. In contrast, all sites inoculated with mixtures of 20% or 5% ONYX-015-infected C33A or HLaC tumor cells remained tumor-free for the duration of the study (8 weeks after inoculation) ( Table 2 ). Animals receiving a mixture containing 1% infected C33A cells developed tumors in all four sites by week 8, although the mean tumor volume (470 mm 3 Ϯ 170) was only 19% of the mean for the uninfected control group (2180 mm 3 Ϯ 760; P ϭ .15) (Fig 1) .
As expected, sites inoculated with the resistant U87 cell line infected with ONYX-015 grew tumors in almost all cases ( Table 2) . Seven of eight sites inoculated with 20% infected cells developed progressive tumors, as did all eight sites inoculated with 5% infected cells. In contrast, infection with wild-type Ad, which replicates in U87 cells, prevented tumor formation at all eight sites inoculated with a 20% infected cell mixture and prevented growth in seven of eight sites at 5%. Therefore, Figure 1 . Tumor growth inhibition after preinfection of C33A, p53-deficient tumor cells with ONYX-015. C33A tumor cells were infected with ONYX-015 and subsequently mixed with an uninfected cell suspension, resulting in preinfection of 20%, 5% (F), or 1% (f) of cells (n ϭ 4 inocula per group). Uninfected cells were used as controls (n ϭ 8, Ⅺ). A total of 10 7 cells were then injected into the flanks of nude mice, and inoculation sites were followed weekly for tumor growth. No growth was seen with either 20% or 5% preinfection. these results demonstrate that efficacy in this preinfection and mixing model correlates with viral replication.
Efficacy of repeat dosing versus a single i.t. injection
To increase virus distribution using direct i.t. injection, we administered ONYX-015 injections daily for 5 consecutive days. This treatment regimen was significantly more effective at inhibiting HLaC tumor growth than was a single administration of the same total dose of virus (Fig 2) . The mean tumor volume at 3 weeks after treatment with the single dose regimen was 453 mm 3 (Ϯ 130) versus 145 mm 3 (Ϯ 38) with the multiple dose regimen (P ϭ .04). Partial regressions were seen in three of eight cases in the multiple dose group (two near complete remissions), whereas two minor regressions occurred in the single dose group. Similar results have been documented with C33A tumors (data not shown).
Effects of virus suspension volume on efficacy and i.t. distribution
Tumors treated with virus suspended in the high volume were significantly more growth inhibited than were those treated with the same total virus dose suspended in a low volume (Fig 3A) . The mean tumor volume (6 weeks posttreatment) was 1617 mm 3 (Ϯ 340) for the low volume group and 605 mm 3 (Ϯ 120) for the higher suspension volume group (P ϭ .04). In addition, partial regressions were seen in four of eight tumors treated with the high suspension volume but were not seen in any of the eight tumors in the low suspension volume group (Fisher's exact test: P ϭ .05). The control group, which was treated with UV-inactivated virus in identical fashion to the high volume suspension group, had a mean tumor volume of 2312 mm 3 (Ϯ 405). To confirm that virus suspension volume correlated with i.t. virus distribution, C33A tumors were injected with a single dose of 10 8 PFU of ONYX-015 diluted in either 40 L or 100 L of PBS. Four mice in the high and low volume groups were euthanized at 3 or 5 days postinjection. In situ hybridization for Ad DNA was done on tumor sections to assess the localization of virus-infected cells. At 3 days postinjection, tumors that received 100 L showed infected cells at both the periphery and central areas of the tumor, whereas tumors injected with 40 L had infection localized in more central areas near the site of injection. By 5 days, both treatments showed significant tumor cell infection; however, tumors that received the high volume showed a more widespread distribution of infected cells, whereas the low-volume dosing generally appeared to result in dissemination from the center to outer areas (Fig 3, B and C).
DISCUSSION
Virus-based therapeutics hold promise as anti-cancer agents. Nonreplicating viral gene therapy vectors and selectively replication-competent viruses may achieve a broad therapeutic index between normal cells and cancer cells. Thus, increased efficacy and decreased toxicity compared with existing chemotherapies may be possible with these genetically targeted approaches. 13, 14 The eventual efficacy of these virus-based approaches will be dependent upon the efficient targeting and killing of cancer cells within solid tumor masses.
In the present studies, we have demonstrated that i.t. virus distribution can have a profound effect on antitumoral efficacy. Viral replication and spread to adjacent cells within a tumor mass has been documented. Preinfection of as few as 5% of tumor cells within a mass prevented tumor formation. This degree of "bystander effect" compares favorably with other strategies in the killing of tumor cells that are not infected at the time of treatment with nonreplicating viral vectors (e.g., prodrug-activating enzyme therapy). 2, 15, 16 However, the spread of the virus within a tumor mass appears to be less efficient than the replication of the virus itself. Although i.t. viral titers increased by 100-to 1000-fold over 72 hours following intravenous injection; 17 it is unlikely that each one of these newly produced viruses will immediately infect a previously uninfected cell. Preinfection of 1% of tumor cells resulted in significant growth inhibition but did not prevent tumor formation. We subsequently demonstrated that mechanically distributing the virus within the tumor at the time of injection led to enhanced antitumoral efficacy. Human tumor xenografts in nude mice are not as complex in structure as human tumors; viral distribution in the presence of fibrosis and tumor cell/normal cell heterogeneity would presumably be less efficient in human tumors. Phase I clinical trial results in head and neck cancer patients receiving i.t. injections with ONYX-015 have supported the evidence presented in the murine model. Patients receiving five daily doses of ONYX-015 were more likely to experience significant tumor necrosis than those receiving single i.t. injections. 18 There are many potential barriers to viral dissemination within a tumor. For example, pressure gradients, binding to extracellular matrix components, and limited convection may combine to limit i.t. spread. It is known that these factors limit the spread of macromolecules, such as monoclonal Abs, within the tumor microenvironment. 9 Replicating viral therapy such as with ONYX-015 may also be limited by fibroblasts within a tumor, because these cells have functional p53 and therefore do not efficiently replicate the virus. 6 In addition, both specific (e.g., neutralizing Abs or cytotoxic T cells) and nonspecific (e.g., phagocytes or anti-viral cytokines) immune response mechanisms may also limit spread of the virus. It is clear that intravascular administration of Ad elicits a potent immune response. 19, 20 The response to i.t. delivery, however, is not well defined. Within 24 hours after intravenous administration, 90% of the adenoviral vector is eliminated from the mouse liver, 21 indicating the involvement of innate immune mechanisms. The innate immunity of athymic nude mice is intact. However, T-cell-mediated and humoral responses, which are known to be important factors in the long-term response to Ad, cannot be addressed in human tumor xenograft models. Neutralizing Abs, however, are unlikely to target i.t. virus efficiently given their limited dissemination within the tumor mass. In phase I clinical trials of i.t. ONYX-015 injection, the presence of neutralizing Abs in patients before treatment initiation has not precluded efficacy. 18 Finally, tumors will undoubtedly vary in their vascularization by blood vessels and/or lymphatics, both avenues by which a virus may disseminate throughout a solid tumor. 22, 23 It is evident that both the numbers of tumor cells infected and their distribution within a tumor mass will impact efficacy. In addition to physically spreading the virus within the tumor at the time of injection, other strategies may also enhance efficacy. For example, intravascular administration of the virus leads to infection of the tumor diffusely throughout its advancing rim. 12 This is in contrast to the initially focal distribution of infection after i.t. injection. Another potential approach includes altering the microenvironment of the tumor to allow better viral spread. In conclusion, methods that increase the number of tumor cells infected and/or their distribution within a mass should improve antitumoral efficacy and allow virus-based therapies to achieve their full therapeutic potential.
